Growth Hormone Deficiency Market Share

Geographically, the growth hormone deficiency market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.

North America industry is expected to hold largest revenue share by 2036, attributed to factors such as high healthcare expenditure, and amplified intake of human growth hormone therapies in the region in order to cure different syndromes such as Turner syndrome. Further, the ease of availability of artificial growth hormones, rise in research and development concerning human growth hormone, and the availability of reimbursements are further contributing towards the regional growth.

The European region is anticipated to hold the second-largest market share in the growth hormone deficiency market. The growth in this region is attributed to the rising incidences of growth hormone deficiencies, increasing inclination towards growth hormones for the treatment of Idiopathic Short Stature (ISS), and rising government spending for the healthcare facilities in the region.

Asia-Pacific is estimated to grow at the fastest rate during the forecast period. Factors such as a rise in the incidence of growth hormone deficiency disorders, upsurge in healthcare expenditure, infiltration of leading players, growing population, and a rise in disposable income, are projected to propel the growth in the Asia-Pacific region.